Yokogawa and HIROTSU BIO SCIENCE Sign Investment and Partnership Agreement- Collaboration to widen use of N-NOSE cancer screening test -

东京,日本-2021年2月16日

德赢vwin开户
HIROTSU生物SCIENCE INC.

德赢vwin开户横河电机株式会社(东京:6841)和广通生物科学公司(HIROTSU BIO-SCIENCE INC.)宣布,他们已经签署了一项投资和合作协议,目标是扩大HBS的N-NOSE的使用®癌症筛查测试服务,利用线虫高度敏感的嗅觉功能来检测癌症。根据该协议,横河将投资于HBS,并负责N-NOSE自动分析设备的制造和维护。两家公司还致力于开发新的自动分析设备,促进N-NOSE业务的全球增长。

From left: Hiroshi Nakao, a Yokogawa vice president and head of the Life Innovation Business Headquarters; Takaaki Hirotsu, HBS’s president and CEO
From left: Hiroshi Nakao, a Yokogawa vice president and head of the Life Innovation Business Headquarters; Takaaki Hirotsu, HBS’s president and CEO
Zoom

癌症筛查的问题包括早期发现癌症的困难,以及没有足够的人进行这些检测,这可归因于缺乏一种能够以高准确度和低成本轻松检测多种癌症的初步筛查检测方法。在COVID-19大流行期间,这些问题变得特别严重,因为许多患有基础疾病的人不愿意通过到医疗机构接受检测来冒险接触病毒。

The N-NOSE service presents a solution to these issues, but to provide this service to a broader segment of the market, HBS must now scale up the production of its automatic analysis equipment. With Yokogawa's manufacturing capacity and life science know-how, the two companies will be able to build a system for the mass production and maintenance of this automatic analysis equipment and meet the expected growth in demand for testing. They will also explore collaboration in the development of next-generation automatic analysis equipment and the global expansion of the N-NOSE business. For this business, HBS will provide nematode cancer screening technology and know-how, and Yokogawa will leverage its core measurement, control, and information technologies, and a global network that spans 62 countries.

为了分担这些合作活动的风险和回报,两家公司同意采用IT软件和系统领域许多公司采用的相同收入分享方法。

The N-NOSE primary screening service uses nematodes, organisms that are about one millimeter long, have an excellent sense of smell, and are inexpensive to nurture, to detect cancer from trace amounts of odorants in urine samples. HBS research has found that nematodes are able to detect at a very early stage (0 or 1) 15 different cancers*1,包括胃癌、结直肠癌和肺癌,概率约为86%*2. 这种全面的癌症检测只需要一次性提交尿样,而且与目前可用的其他检测相比,成本要少得多。

在完成了自己的自动分析设备的开发之后,哈佛商学院于2020年1月推出了N-NOSE服务。为应对COVID-19流感大流行,该公司目前正计划于2021年春季在日本推出一项可以在家进行的“N鼻在家”服务。

关于这一合作关系,哈佛商学院总裁兼首席执行官Takaki Hirotsu评论道:“N-NOSE是一种线虫癌症测试,旨在成为全世界所有人的年度测试,作为癌症的初步筛查测试。为了实现这一目标,自动化分析系统的高通量、大规模生产和全球支持是必不可少的,我们认为与横河电气公司的联盟对促进N-NOSE业务至关重要。这个项目的另一个特点是,我们将采用硬件技术的收入分享方法,这是非常罕见的。这是一家风险公司和一家大公司之间的一种新的合作形式,我们希望能从中创造出改变世界的新价值。”德赢vwin开户

横河总裁兼首席执行官Hitoshi Nara说,“对横河来说,这一合作是实现所有人福祉的重要共同创新举措,这是我们可持续发展的“三大目标”之一,我们相信这将对社会作出重大贡献。我们将以此协议为起点,与广通生物科技建立牢固的关系,并致力于进一步的价值共同创造。”

*1胃、大肠、肺、乳腺、胰腺、肝、前列腺、子宫、食管、胆囊、胆管、肾、膀胱、卵巢、口咽
*2 Based on data compiled by the Japanese Association for Cancer Prevention (June 2019), the Japan Society of Ningen Dock (July 2019), and the Japanese Association for Cancer Detection and Diagnosis (August 2019)

HIROTSU生物SCIENCE INC.

德赢vwin开户

  • Founded: September 1915
  • 总裁兼首席执行官:Hitoshi Nara
  • Business: Manufacture, sales, and maintenance services for industrial control and measurement equipment, etc.
  • 网站://www.zhisiyu.com/

The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of HIROTSU BIO SCIENCE INC., Yokogawa Electric Corporation, or their respective holders.

Related Products & Solutions

Life Innovation

通过使用测量、控制、信息技术和生命科学,从根本上提高整个价值链的生产力,从基础研究到物流和服务。

Top